Page last updated: 2024-11-13

3-hydroxy-5-cholestenoic acid, (3beta,25r)-isomer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cholestenoic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(25R)-3beta-hydroxycholest-5-en-26-oic acid : A 3beta-hydroxycholest-5-en-26-oic acid in which the stereocentre at position 25 has R-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID40579073
CHEBI ID86378
SCHEMBL ID17413741
MeSH IDM0318338

Synonyms (22)

Synonym
cholestenoic acid
LMST04030072 ,
3beta-hydroxycholest-5-en-25r-26-oic acid
hydroxycholestenoic acid
CHEBI:86378
(25r)-3beta-hydroxycholest-5-en-26-oic acid
SCHEMBL17413741
56845-87-5
3-hydroxy-5-cholestenoate
3 beta-hydroxycholest-5-en-27-oate
3beta-hydroxy-5-cholesten-26-oate
(3beta)-3-hydroxy-cholest-5-en-26-oate
(3beta)-3-hydroxy-cholest-5-en-26-oic acid
3-hydroxy-5-cholesten-26-oate
3 beta-hydroxycholest-5-en-27-oic acid
Q27159118
(3beta,25r)-3-hydroxycholest-5-en-26-oic acid
DTXSID701267672
CS-0646545
5-cholestene-26-oic acid-3|a-ol
cholest-5-en-26-oic acid, 3-hydroxy-, (3beta,25r)-
HY-N11299
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
3beta-hydroxycholest-5-en-26-oic acidA steroid acid resulting from the oxidation of one of the terminal methyl groups of cholesterol to the corresponding aldehyde.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Oxysterols derived from cholesterol3831

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (15.79)29.6817
2010's13 (68.42)24.3611
2020's3 (15.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]